Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 11/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.53 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6128238 | 0.94 | PRCP (0.70) | PRCPCYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL16499272 | 0.94 | PRCP (0.56) | PRCPCYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL15848586 | 0.94 | PRCP (0.56) | PRCPCYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL15848588 | 0.94 | PRCP (0.56) | PRCPCYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL3448550 | 0.93 | PRCP (0.55) | PRCPCYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL15848395 | 0.93 | PRCP (0.57) | PRCPCYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL15848419 | 0.93 | PRCP (0.68) | PRCPCYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL15848314 | 0.93 | PRCP (0.68) | PRCPCYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL15848315 | 0.93 | PRCP (0.68) | PRCPCYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL15848417 | 0.93 | PRCP (0.68) | PRCPCYP3A4CYP2C9NR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227961-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-05 | — | — | US | claimed |
| US-20150011754-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-01-08 | — | — | US | claimed |
| EP-2049522-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-05-14 | — | — | EP | claimed |
| EP-2049522-A2 | HEPATITIS C VIRUS INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-04-22 | — | — | EP | claimed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | claimed |
| WO-2008021927-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | claimed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| WO-2016178250-A1 | PROCESS FOR THE PREPARATION OF DACLATASVIR | MYLAN LABORATORIES LIMITED (IN) | 2016-11-10 | — | — | WO | disclosed |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-27 | — | — | US | disclosed |
| US-9421192-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-23 | — | — | US | disclosed |
| WO-2016079697-A1 | PROCESS FOR THE PREPARATION OF AN INTERMEDIATE OF DACLATASVIR DIHYDROCHLORIDE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-05-26 | — | — | WO | disclosed |
| US-20160067223-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| EP-2242752-A1 | IMIDAZOLYL BIPHENYL IMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-10-27 | — | — | EP | disclosed |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
| WO-2009102325-A1 | IMIDAZOLYL BIPHENYL IMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
| EP-2049522-A2 | HEPATITIS C VIRUS INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-12 | — | — | US | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
| WO-2008021927-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067223-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PRCP 190/4885CYP3A4 1107/4885CYP2C9 2585/4885 |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PRCP 190/4885CYP3A4 1107/4885CYP2C9 2585/4885 |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | PRCP 190/4885CYP3A4 1107/4885CYP2C9 2585/4885 |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | PRCP 190/4885CYP3A4 1107/4885CYP2C9 2585/4885 |
| US-20150011754-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PRCP 190/4885CYP3A4 1107/4885CYP2C9 2585/4885 |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PRCP 190/4885CYP3A4 1107/4885CYP2C9 2585/4885 |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PRCP 190/4885CYP3A4 1107/4885CYP2C9 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.